Prevention and management of bone metastases in lung cancer a review

Journal of Thoracic Oncology

Volumn 4, Issue 2, 2009, Pages 251-259

  Husaini Dr , Hamed Al ^a   Wheatley Price Dr , Paul ^b   Clemons Dr , Mark ^b   Shepherd, Frances A ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Bisphosphonates; Bone metastases; Lung cancer

Indexed keywords

AMG 142; AMINO TERMINAL TELOPEPTIDE; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CLODRONIC ACID; CORTICOSTEROID DERIVATIVE; DENOSUMAB; DOCETAXEL; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE DESTRUCTION; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCALCEMIA; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LOADING DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; SPINAL CORD COMPRESSION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; BONE TUMOR; LUNG TUMOR; METASTASIS; PATHOLOGY;

BONE NEOPLASMS; HUMANS; LUNG NEOPLASMS;

EID: 65649115867     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31819518fc     Document Type: Review

References (86)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80: 1588-1594.
2. Quint LE, Tummala S, Brisson LJ, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 1996;62:246-250.
3. Nottebaert M, Exner GU, von Hochstetter AR, Schreiber A. Metastatic bone disease from occult carcinoma: a profile. Int Orthop 1989;13:119-123.
4. Kosteva J, Langer C. Incidence and distribution of skeletal metastases in the era of PET. Lung Cancer 2004;46:S45.
5. Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K. Bone metastasis as the first manifestation of lung cancer. Int J Clin Pract 2003;57:184-186. (Pubitemid 36511776)
6. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 1997;69:1-18.
7. Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer 2004;6:170-174.
8. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57:229-232. (Pubitemid 47044952)
9. Diel IJ, Mundy GR. Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer 2000;82:1381-1386.
10. Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 2005;65:11001-11009.
11. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213s- 6216s.
12. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-1549.
13. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93: 165-176.
14. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655-1664.
15. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998;188:997-1001.
16. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-696.
17. Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
18. Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 2008;5:206-219.
19. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584 -593.
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055.
21. Berenson JR, Rajdev L, Broder M. Pathophysiology of bone metastases. Cancer Biol Ther 2006;5:1078-1081.
22. Garfield D, Cadranel J, Normanno N. Osteoblastic metastases in nonsmall cell lung cancer and its possible significance. Lung Cancer 2008;60:146-147.
23. van der Pluijm G, Sijmons B, Vloedgraven H, Deckers M, Papapoulos S, Löwik C. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001;16:1077-1091.
24. Bellahcene A, Maloujahmoum N, Fisher LW, et al. Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 1997;61:183-188.
25. Papotti M, Kalebic T, Volante M, et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol 2006;24:4818-4824.
26. Deng X, Tannehill-Gregg SH, Nadella MV, et al. Parathyroid hormonerelated protein and ezrin are up-regulated in human lung cancer bone metastases. Clin Exp Metastasis 2007;24:107-119.
27. Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol 2006;1:571-576.
28. Botteman MF, Foley I, Marfatia AA, Brandman J, Langer CJ. Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: the case of the United Kingdom (UK). J Clin Oncol 2007;25:Abstract 6617.
29. Kvale PA, Simoff M, Prakash UB. Lung cancer. Palliative care. Chest 2003;123:284S-311S.
30. Bezjak A. Palliative therapy for lung cancer. Semin Surg Oncol 2003; 21:138-147.
31. Wu JS, Wong RK, Lloyd NS, Johnston M, Bezjak A, Whelan T; Supportive Care Guidelines Group of Cancer Care Ontario. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases - an evidence-based practice guideline. BMC Cancer 2004; 4:71.
32. Chow E, Harris K, Fan G, Tsao M, Sze WM, Wu J. Meta-analysis of palliative radiotherapy trials for bone metastases. Clin Oncol (R Coll Radiol) 2007;19:S26.
33. Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003;55:594-605.
34. Haddad P, Wong RK, Pond GR, et al. Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. Clin Oncol (R Coll Radiol) 2005;17:430-434.
35. Haentjens P, Casteleyn PP, Opdecam P. Evaluation of impending fractures and indications for prophylactic fixation of metastases in long bones. Review of the literature. Acta Orthop Belg 1993; 59(Suppl 1):6-11.
36. Manglani HH, Marco RA, Picciolo A, Healey JH. Orthopedic emergencies in cancer patients. Semin Oncol 2000;27:299-310.
37. Jenis LG, Dunn EJ, An HS. Metastatic disease of the cervical spine. A review. Clin Orthop Relat Res 1999;359:89-103.
38. Hirano Y, Oda M, Tsunezuka Y, Ishikawa N, Watanabe G. Long-term survival cases of lung cancer presented as solitary bone metastasis. Ann Thorac Cardiovasc Surg 2005;11:401-404.
39. Agarwala AK, Hanna NH. Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer 2005;6:367-368.
40. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998;16:3890-3899.
41. Roodman GD. Studies in Paget's disease and their relevance to oncology. Semin Oncol 2001;28:15-21.
42. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999;25:97-106.
43. Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000;60:6001-6007.
44. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000;60:2949-2954.
45. Senaratne SG, Colston KW. Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 2002;4:18-23.
46. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459-1468.
47. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
48. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-854.
49. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-493. (Pubitemid 26067736)
50. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602.
51. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
52. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-387.
53. Coleman RE. Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol 2002;25:S25-S31.
54. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-4284.
55. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-1468.
56. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20(Suppl 2):45-54.
57. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144:753-761.
58. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol 2002; 25:S3-S9.
59. Gao Z, Han B. Effect of zoledronic acid combined with cisplatin for non-small cell lung cancer. J Clin Oncol 2008;26:Abstract 19116.
60. Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormoneresponsive, stage I and II breast cancer: first efficacy results from ABCSG-12. J Clin Oncol 2008;26:LBA4.
61. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-3157.
62. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100:2613-2621.
63. Hirsh V, Major PP, Lipton A, et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008;3:228-236.
64. Brown JE, Hirsh V, Major PP, et al. Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: the role of BALP. J Clin Oncol 2008;26:Abstract 19003.
65. Hatoum HT, Lin S, Lipton A, et al. The impact of zoledronic acid treatment on frequency of skeletal complications experienced and on followup duration post diagnosis of bone metastasis in lung cancer patients. J Clin Oncol 2008;26:Abstract 8106.
66. Rankovic B, Mrdja V. Use of disodium pamidronate in patients with bone metastases in patients with pulmonary carcinoma. Vojnosanit Pregl 2002;59:33-36.
67. Kiagia M, Karapanagiotou E, Charpidou A, et al. Rapid infusion of ibandronate in lung cancer patients with bone metastases. Anticancer Res 2006;26:3133-3136.
68. Kritikos K, Heras P, Hatzopoulos A, et al. Ibandronate and pamidronate in patients with bone metastases from breast or lung cancer: a comparative study. J Clin Oncol 2005;23:Abstract 8283.
69. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004;22:3587-3592.
70. Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. Oncologist 2005;10(Suppl 1):8-13.
71. Caristi N, Russi EG, Adamo V, et al. Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study. G Ital Oncol 1990;10:129-132.
72. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19:1059-1066.
73. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437.
74. Bender RA, Hansen H. Hypercalcemia in bronchogenic carcinoma. A prospective study of 200 patients. Ann Intern Med 1974;80:205-208.
75. Coggeshall J, Merrill W, Hande K, Des Prez R. Implications of hypercalcemia with respect to diagnosis and treatment of lung cancer. Am J Med 1986;80:325-328.
76. Hayward ML Jr, Howell DA, O'Donnell JF, Maurer LH. Hypercalcemia complicating small-cell carcinoma. Cancer 1981;48:1643-1646.
77. Mundy GR. Hypercalcemic factors other than parathyroid hormonerelated protein. Endocrinol Metab Clin North Am 1989;18:795-806.
78. Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer 1997;80:1564-1571.
79. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992;326:1196-1203.
80. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
81. Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. Interna- tional consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002;64:275-280.
82. Chow E, Harris K, Tharmalingam S, et al. Early phase in the development of a bone metastases quality of life module. Clin Oncol (R Coll Radiol) 2007;19:S26.
83. Clamp A, Danson S, Nguyen H, Cole D, Clemons M. Assessment of therapeutic response in patients with metastatic bone disease. Lancet Oncol 2004;5:607-616.
84. Lipton A, Costa L, Ali S, Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 2001;28:54-59.
85. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23:4925-4935.
86. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.